Zacks Investment Research downgraded Exactech, Inc. (NASDAQ:EXAC) to Hold in a report released today.
- Updated: October 4, 2016
Yesterday Exactech, Inc. (NASDAQ:EXAC) traded -0.34% lower at $26.07. The company’s 50-day moving average is $27.55 and its 200-day moving average is $25.21. The last closing price is up 4.95% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 50,623 shares of the stock were exchanged, up from an average trading volume of 33,983
Zacks Investment Research has downgraded Exactech, Inc. (NASDAQ:EXAC) to Hold in a report released on Tuesday October 04, 2016.
See Chart Below
Exactech, Inc. has a 52 week low of $16.11 and a 52 week high of $28.66 with a P/E ratio of 23.84 The company’s market cap is currently $0.
Also covering Exactech, Inc.'s target, a total of 3 equity analysts have released a ratings update on EXAC. The one year target is $22.67 with one brokerage rating the company a strong buy, one brokerage rating the company a buy, two brokerages rating the company a hold, zero brokerages rating the company a underperform, and lastly zero analysts rating the company a sell.
General Company Details For Exactech, Inc. (NASDAQ:EXAC)
Exactech, Inc. develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company's segments include knee implants, hip implants, biologics and spine, extremity implants and other products. Its other products segment includes surgical instruments, bone cement and other implant product lines. The Company offers knee implant systems, including Exactech Knee System and Optetrak Logic. It offers various products and services for the healing and regeneration of bone and soft tissue. Its hip solutions address the continuum of hip arthroplasty. It offers solutions for shoulders with traumatic injuries. Its joint replacement products are used to repair or replace joints that have deteriorated as a result of injury or disease.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.